Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in PFAPA
NCT02775994Phase 1Unknown
- Sponsor
- Rabin Medical Center
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of canakinumab in periodic fever syndrome, sponsored by Rabin Medical Center. Primary endpoint: 50% reduction in PFAPA flares at 2 months. Status: unknown.
02
Drugs
canakinumab
03
Conditions
periodic fever syndrome
Beyond the preview
Go deeper on NCT02775994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775994.